Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults

Brief Summary

Detailed Description

Design: Retrospective postauthorization study. Registry study. Setting: COVID Unit, "Perpetuo Socorro" Hospital of Albacete (Spain). Participants: Adults older than 70 years hospitalized for COVID-19 disease between 09/03/2020 and 20/04/2020. All patients will be included without exclussion criteria. Measurements: * Age, sex, residency. * Functional assessment: Barthel index, Katz index, Functional Ambulation Classification. * Cognitive assessment: Reisberg´s Global Deteriorating Scale. * Comorbidity: Charlson index, disease count. * Chronic medicines consumed. * Disease related symptoms. * Lab determinations: White cells, neutrophyl count, lymphocyte count, platelets, haemoglobin, INR, fibrinogen, D-Dimer, Ferritin, CRP, IL-6, urea, creatinin, AST, ALT, CK. * Thorax X-ray findings: COVID affectation, severity, pleural effusion, heart failure signs, pneumothorax. * Drugs used during hospitalization, number of days of treatment and total doses: Anakinra, Baricitinib, Glucocorticoids, Antivirals (Lopinavir/Ritonavir, Emtricitabina/Tenofovir), Azitromycin, Ceftriaxone, Hidroxychloroquin. * Geriatric syndroms: Delirium, immobility, dysphagia, pressure ulcers. * Outcomes: Mortality at discharge, institucionalización at discharge, length of stay, change in lab results, change in X-ray results, change in function at discharge. Registry procedures: Medical chart review by trained Geriatricians, pharmachological chart review by expert Pharmacists, X-ray review by trained radiologists. All data will be included in an anonimyzed database for further analysis by investigators, and supervised by Principal Investigator. Regulatory status: The protocol was approved by the Ethics review committee of Albacete (number 2020-21 from 20/04/2020) and by the Spanish Medicines Agency (AEMPS) who gave a "Postauthorization Study" classification (number PAS-BAR-2020-04. 20/04/2020). Analysis: Two stage analysis will be conducted. In first one, efficacy and security analysis of the 99 patients that have received either Baricitinib or Anakinra will be conducted, and in the second one, clinical-epidemiological analysis of the complete sample, n=576, will be realized.

Primary Outcomes

Secondary Outcomes

• Disability changes(1 month)
• lymphocyte count changes(1 month)
• C-Reactive Protein changes(1 month)
• Ferritin changes(1 month)
• Ambulation changes(1 month)
• D-Dimer changes(1 month)
• X-ray changes(1 month)